Thalidomide remains an active drug on the pharmaceutical market
the verdict
SUPPORTED
the evidence backs this
confidence 79/100
Thalidomide remains an active drug on the pharmaceutical market, having successfully transitioned from its historical withdrawal to a widely studied and utilized repurposed agent for multiple myeloma, immunological conditions, and inflammatory disorders.
Evidence for · 7
Discovering Potential in Non-Cancer Medications: A Promising Breakthrough for Multiple Myeloma Patients.
2024 · cited by 3
Thalidomide is highlighted as a successful repurposed drug for treating conditions like multiple myeloma.
See more details
More for · 6
A review of thalidomide and digestive system related diseases.
2025 · cited by 2
The drug remains in clinical use and is actively studied for digestive disorders and other conditions despite past controversies.
Drug Repurposing in Veterinary Oncology: Myth or Reality?
2025 · cited by 1
Thalidomide is classified as an active immunomodulatory therapeutic agent in veterinary oncology and human medicine.
Renaissance of Phoenix Drug Thalidomide-New Insights into Practical Clinical Application and Optimization Strategies for Managing Adverse Effects in Digestive Diseases.
2025 · cited by 0
Thalidomide has re-emerged as a repurposed agent for a broad spectrum of diseases, acting as a modern phoenix drug.
Successful Remission of Refractory Oral Ulcers Treated with Low-Dose Thalidomide and Colchicine: A Case Report.
2026 · cited by 0
Low-dose thalidomide is successfully prescribed in clinical case reports for the treatment of refractory oral ulcers.
Tofacitinib combined with fire needle therapy for refractory cutaneous Rosai-Dorfman disease: a first case report and literature review.
2026 · cited by 0
Clinical histories document patients receiving thalidomide as part of established pharmacological interventions for immunological conditions.
Multi-omics Analysis Reveals the Correlation of Gut Microbiota and Metabolites With Thalidomide Treatment for Chemotherapy-Induced Nausea and Vomiting in Small Cell Lung Cancer.
2026 · cited by 0
Thalidomide is actively utilized in clinical settings to manage chemotherapy-induced nausea and vomiting in cancer patients.